These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34304802)

  • 1. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy.
    Kharfan-Dabaja MA; Kumar A; Ayala E; Aljurf M; Nishihori T; Marsh R; Burroughs LM; Majhail N; Al-Homsi AS; Al-Kadhimi ZS; Bar M; Bertaina A; Boelens JJ; Champlin R; Chaudhury S; DeFilipp Z; Dholaria B; El-Jawahri A; Fanning S; Fraint E; Gergis U; Giralt S; Hamilton BK; Hashmi SK; Horn B; Inamoto Y; Jacobsohn DA; Jain T; Johnston L; Kanate AS; Kansagra A; Kassim A; Kean LS; Kitko CL; Knight-Perry J; Kurtzberg J; Liu H; MacMillan ML; Mahmoudjafari Z; Mielcarek M; Mohty M; Nagler A; Nemecek E; Olson TS; Oran B; Perales MA; Prockop SE; Pulsipher MA; Pusic I; Riches ML; Rodriguez C; Romee R; Rondon G; Saad A; Shah N; Shaw PJ; Shenoy S; Sierra J; Talano J; Verneris MR; Veys P; Wagner JE; Savani BN; Hamadani M; Carpenter PA
    Transplant Cell Ther; 2021 Aug; 27(8):642-649. PubMed ID: 34304802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT.
    Sureda A; Carpenter PA; Bacigalupo A; Bhatt VR; de la Fuente J; Ho A; Kean L; Lee JW; Sánchez-Ortega I; Savani BN; Schetelig J; Stadtmauer EA; Takahashi Y; Atsuta Y; Koreth J; Kröger N; Ljungman P; Okamoto S; Popat U; Soiffer R; Stefanski HE; Kharfan-Dabaja MA
    Bone Marrow Transplant; 2024 Jun; 59(6):832-837. PubMed ID: 38443706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes.
    Llaurador G; Nicoletti E; Prockop SE; Hsu S; Fuller K; Mauguen A; O'Reilly RJ; Boelens JJ; Boulad F
    Transplant Cell Ther; 2021 Sep; 27(9):780.e1-780.e14. PubMed ID: 34082161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor-Specific HLA Antibodies Are Associated with Graft Failure and Delayed Hematologic Recovery after Unrelated Donor Hematopoietic Cell Transplantation.
    Lima ACM; Getz J; do Amaral GB; Loth G; Funke VAM; Nabhan SK; Petterle RR; de Marco R; Gerbase-DeLima M; Pereira NF; Bonfim C; Pasquini R
    Transplant Cell Ther; 2023 Aug; 29(8):493.e1-493.e10. PubMed ID: 37220839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
    Baron F; Sandmaier BM
    Leukemia; 2006 Oct; 20(10):1690-700. PubMed ID: 16871276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
    Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
    Baron F; Baker JE; Storb R; Gooley TA; Sandmaier BM; Maris MB; Maloney DG; Heimfeld S; Oparin D; Zellmer E; Radich JP; Grumet FC; Blume KG; Chauncey TR; Little MT
    Blood; 2004 Oct; 104(8):2254-62. PubMed ID: 15226174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft failure after allogeneic hematopoietic stem cell transplantation.
    Ozdemir ZN; Civriz Bozdağ S
    Transfus Apher Sci; 2018 Apr; 57(2):163-167. PubMed ID: 29724627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Chimerism Dynamics after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Nonmalignant Diseases.
    Faraci M; Bagnasco F; Leoni M; Giardino S; Terranova P; Subissi L; Di Duca M; Di Martino D; Lanino E
    Biol Blood Marrow Transplant; 2018 May; 24(5):1088-1093. PubMed ID: 29292059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
    Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
    JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation.
    Alvarez M; Pierini A; Simonetta F; Baker J; Maas-Bauer K; Hirai T; Negrin RS
    Front Immunol; 2020; 11():614250. PubMed ID: 33488624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation].
    Tang XW; Wu DP; Zhu ZL; Wang W; Sun AN; Qiu HY; Fu ZZ; Chang WR; Ruan CG
    Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):78-81. PubMed ID: 14990044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
    Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
    Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
    Hoff FW; Chung SS; Patel PA; Premnath N; Khatib J; Tadic-Ovcina M; AhmedRabie A; Helton D; Yohannes S; Shahan J; Patel H; Geethakumari PR; Vusirikala M; Collins RH; Madanat YF
    Transpl Immunol; 2023 Apr; 77():101808. PubMed ID: 36842566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
    Slavin S; Nagler A; Naparstek E; Kapelushnik Y; Aker M; Cividalli G; Varadi G; Kirschbaum M; Ackerstein A; Samuel S; Amar A; Brautbar C; Ben-Tal O; Eldor A; Or R
    Blood; 1998 Feb; 91(3):756-63. PubMed ID: 9446633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
    Koster EAS; von dem Borne PA; van Balen P; van Egmond EHM; Marijt EWA; Veld SAJ; Jedema I; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; de Wreede LC; Halkes CJM
    Transplant Cell Ther; 2023 Apr; 29(4):268.e1-268.e10. PubMed ID: 36587743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
    Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Sahebi F; Eikema DJ; Koster L; Kroger N; Meijer E; van Doesum JA; Rovira M; Koc Y; Angelucci E; Blaise D; Sammassimo S; McDonald A; Arroyo CH; Sanchez JF; Forcade E; Castagna L; Stölzel F; Sanz J; Tischer J; Ciceri F; Valcarcel D; Proia A; Hayden PJ; Beksac M; Yakoub-Agha I; Schönland S
    Transplant Cell Ther; 2021 Dec; 27(12):999.e1-999.e10. PubMed ID: 34543768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.